In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Israeli biotech D-Pharm completes IPO on TASE

Executive Summary

D-Pharm (small-molecule lipid analogs) has raised NIS85mm ($23mm) in a concurrent initial public offering on the Tel Aviv Stock Exchange, which was oversubscribed and brought in NIS28mm, and a rights offering of NIS57mm. Through both financings a total of 639k shares were sold for NIS133, 13% higher than the low end of the price range.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies